Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3387-3391

  Reddy, Bandaru S ^a   Kawamori, Toshihiko ^a   Lubet, Ronald A ^b   Steele, Vernon E ^b   Kelloff, Gary J ^b   Rao, Chinthalapally V ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZOXYMETHANE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; APOPTOSIS; AZOXYMETHANE; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; NEOPLASM INVASIVENESS; RATS; RATS, INBRED F344; SULINDAC; WEIGHT GAIN;

EID: 0033565252     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parker, S. L., Tong, T., Beiden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 52-64, 1997.
2. Greenwald, P., and Kelloff, G. J. The Role of Chemoprevention in Cancer Control. IARC Sci. Publ. No. 139, pp. 13-22. Lyon, France: IARC, 1996.
3. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1993.
4. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
5. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
6. Reddy, B. S., Rao, C. V., Rivenson, A., and Kelloff, G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (Lond.), 14: 1493-1497, 1993.
7. Rao, C. V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B. S. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res., 55: 1464-1472, 1995.
8. Reddy, B. S., Tokumo, K., Kulkarni, N., Aligia, C., and Kelloff, G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis (Lond.), 13: 1019-1023, 1992.
9. Pollard, M., and Luckert, P. H. Effect of piroxicam on primary intestinal tumors induced by N-methylnitrosourea. Cancer Lett., 25: 117-121, 1984.
10. Narisawa, T., Satoh, M., Sano, M., and Takahashi, T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by nonsteroid anti-inflammatory agent indomethacin. Carcinogenesis (Lond.), 4: 1225-1227, 1983.
11. min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 50: 710-714, 1996.
12. Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove, W. F., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis (Lond.), 17: 1757-1760, 1996.
13. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J. T., Abreu-Goris, M., Newmark, H., Lipkin, M. L., DeCosse, J. J., and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
14. Reddy, B. S., Maruyama, H., and Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47: 5340-5346, 1987.
15. Samaha, H. S., Kelloff, G. J., Steele, V., Rao, C. V., and Reddy, B. S. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexylisothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res., 57: 1301-1305, 1997.
16. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52: 5575-5589, 1992.
17. Eberhart, C. E., Coffey, R. I., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
18. Dujovne, C. A., Pitterman, A., Vincek, W. C., Dobrinska, M. R., Davies, R. O., and Duggan, E. E. Enterohepatic circulation of sulindac and metabolites. Clin. Pharmacol. Ther., 33: 172-177, 1983.
19. Hucker, H. B., Stauffer, S. C., White, S. D., Rhodes, R. E., Arison, B. H., Umbenhauer, E. R., Bower, R. J., and McMahon, F. G. Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1[p-(methyl-sulfinyl)-benzylidenyl]-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab. Dispos., 1: 721-736, 1973.
20. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Richie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2902-2915, 1997.
21. Duggan, D. E., Hooke, K. F., Risley, E. A., Shen, T. Y., and Van Arman, C. G. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther., 201: 8-13, 1977.
22. Mahmoud, N. N., Boolbool, S. K., Dannenberg, A. J., Mestre, J. R., Bilinski, R. T., Martucci, C., Newmark, H. L., Chadburn, A., and Bertagnolli, M. M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis (Lond.), 19: 87-91, 1998.
23. min/+ mouse with R-flurbiprofen (R-FB) and sulindac sulfone. Proc. Am. Assoc. Cancer Res., 39: 643, 1998.
24. Tsujii, M., and Dubois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.
25. Pozharisski, K. M. Tumors of the intestines. Pathology of Tumors in Laboratory Animals. IARC Publ. No. 99, pp. 159-198. Lyon, France: IARC, 1990.
26. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58; 409-412, 1998.
27. Kawamori, T., Lubet, R., Steele, V. E., Kelloff, G. J., Kaskey, R. B., Rao, C. V., and Reddy, B. S. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during promotion/progression stage of colon cancer. Cancer Res., 59: 597-601, 1999.
28. Kargman, S. L., O'Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., and Jothy, S. Expression of prostaglandin G/H-synthase-1 and -2 protein in human colon cancer. Cancer Res., 55: 2556-2559, 1995.
29. DuBois, R. N., Radhika, A., Reddy, B. S., and Entingh, A. J. Increased cycloxygenase-2 levels in carcinogen-induced rat colon tumors. Gastroenterology, 110: 1259-1262, 1996.
30. Singh, J., Hamid, R., and Reddy, B. S. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res., 57: 3465-3470, 1997.
31. ΔD716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell, 87: 803-809, 1996.
32. Shiff, S. J., Qiao, L., Tsai, L., and Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Investig., 96: 491-503, 1995.